How peptide impurities are born: what can go wrong between synthesis and storage

Peptide impurities are any components of a peptide sample other than the intended peptide. Some are the peptide itself in altered form: a residue missing or modified, or a change in structure. Others are process residues that remain after manufacturing. In research peptides, most impurities can be traced to synthesis, to cleavage and deprotection, or to degradation that continues during processing and storage. Deletion and truncated sequences, oxidized and deamidated forms, and residual solvents or reagents are among those encountered most often. Their origins differ, and so does how much each one matters. Some form before the peptide is even fully assembled. Others show up after purification, in a batch that met its purity specification when it was tested. Knowing where a change is likely to happen makes analytical results easier to read, and it gives researchers a place to start when experiments don’t agree with each other. What are peptide impurities? Put simply, an impurity is any component of the sample that isn’t the intended peptide. It may be a modified copy of the peptide, or something left over from making it. Analysts usually sort impurities into two groups. Peptide-related impurities form the first group. Think of them as near-copies of the target: a residue lost or gained, a side chain carrying the wrong chemical group, a stereocenter flipped. Deletion sequences belong here, and so do oxidized and deamidated peptides. The second group covers everything that isn’t peptide: residual solvents, leftover synthesis reagents and other process residues. Water and counterions are a slightly different case. A peptide purified with TFA usually ends up as its trifluoroacetate salt, or as an acetate after counterion exchange, and a little water nearly always stays behind. Both tend to be reported on their own rather than lumped in with impurities. The split matters for understanding  peptide purity . An HPLC purity percentage describes the relative share of the components that were detected, under one particular method. It doesn’t tell you how much peptide is in the vial by weight. That second number is net peptide content, and the gap between the two is most noticeable in research materials supplied as lyophilized powder. Stage 1 – How impurities form during peptide synthesis Most synthetic research peptides come from solid-phase peptide synthesis, or SPPS. The growing chain sits on resin beads, and amino acids go on one by one. Every cycle has to run almost to completion; if it doesn’t, the mistake stays in that chain for the rest of the synthesis. Maybe a residue fails to couple, or couples where it shouldn’t. Maybe a step stops partway, or a side reaction changes the chain. Each of these ends up as an impurity. Longer sequences give these events more chances to happen. D’Hondt and colleagues review the main classes of peptide-related impurities linked to synthesis and later processing. Missing, extra and incomplete sequences Three sequence-related impurities come up most often: Deletion sequences: one or more amino acids are missing, typically because a coupling step didn’t go all the way. Insertion sequences: an extra amino acid has slipped into the chain. Truncated sequences: the chain stopped growing before it reached full length. Because these variants differ from the target by so little, they’re hard to tell apart from it. Remove a single amino acid and the peptide may run through a chromatography column almost exactly like the full-length one, which is what makes it so stubborn to separate. Protecting groups add another complication. If one isn’t fully removed between cycles, it can get in the way of the next coupling and generate products nobody wanted. Racemization and aspartimide formation Some synthesis impurities don’t involve adding or losing an amino acid at all. Racemization (or epimerization) changes the stereochemical configuration of a residue. The product can have exactly the same mass as the target and a different three-dimensional shape. Aspartimide formation is a recognized side reaction in sequences with susceptible aspartic acid residues. It runs through a cyclic intermediate, which then gives rise to further peptide variants. How likely these reactions are depends on the sequence, the reagents and the reaction conditions. Peptide length alone won’t tell you whether they happened. Stage 2 – What can go wrong during cleavage and purification Once synthesis is finished, the peptide has to be released from its solid support and its remaining protecting groups taken off. This is where cleavage-related impurities come from. The reactions don’t always finish, and the chemical conditions can modify the peptide in ways nobody intended. A protecting group may survive the treatment and stay on the peptide. The strong acid used for cleavage, usually a TFA-based cocktail, can also damage sensitive residues: reactive carbocations released from protecting groups, for example, can alkylate tryptophan or methionine if scavengers don’t trap them first. What you have at this point is crude peptide, the target molecule mixed with synthesis by-products and other process-related material. Why purification cannot remove every impurity The workhorse for purifying synthetic peptides is reversed-phase high-performance liquid chromatography (RP-HPLC) . It separates molecules mainly by hydrophobicity, meaning how strongly they are retained by the column relative to the mobile phase. The trouble is that a near-copy of the target is retained almost as strongly as the target itself. A deletion sequence, a stereochemical variant or a chemically modified peptide can elute right beside the main peak, and with some methods it is never fully resolved. So the outcome depends on three things: the peptide itself, the particular impurities in the crude material, and how selective the chosen method is. A high reported purity doesn’t mean every possible impurity is gone. Stage 3 – Can freeze-drying introduce new problems? After purification, the peptide is usually freeze-dried, or lyophilized. The solution is frozen, the ice sublimes off under vacuum, and what remains is a dry powder or cake. Once the liquid water is gone, many peptides keep far better than they would in solution. That said, freeze-drying doesn’t clean anything up. Non-volatile components of the solution end up in the powder, and degradation carries on afterwards, typically at a slower pace. Nor is the powder ever completely dry. Many peptides are hygroscopic, so some residual water stays bound, and counterions from synthesis and purification add to the weight too. An HPLC purity figure accounts for neither. Net peptide content does, which is why the two numbers for one vial can sit noticeably apart. The drying process itself also has to be matched to the peptide, because stability hinges on the sequence, the formulation and the processing conditions. A lyophilized peptide shouldn’t be treated as chemically inert. Stage 4 – How storage and handling change peptide composition Synthesis and purification end; the chemistry doesn’t. A peptide keeps changing slowly over time, and those changes are where storage-related impurities come from. Which reactions take the lead comes down mostly to the sequence and to what the material is exposed to. Oxidation and disulfide bonds Not all residues are equally sensitive to oxidation. Methionine is one of the most vulnerable. Oxidation first gives methionine sulfoxide, roughly 16 Da heavier than the parent residue; push harder and you get the sulfone, at +32 Da. Then there’s cysteine. Two free thiol groups can join through a disulfide bond, either within the same chain or across two molecules, and that’s how dimers and bigger oligomers appear. Tryptophan isn’t immune either. How quickly any of this happens depends on oxygen, light, trace metal ions and pH, and no two peptides respond quite the same way. Deamidation and hydrolysis: